GnRH agonists inhibit growth and reduce the size of ER-positive tumors, as evidenced in several reports that mainly involved premenopausal women in whom GnRH agonists were used to reduce tumor size preoperatively[10,20] or prevent progression postoperatively, with some cases achieving complete remission.[2,21] From January 2011 to March 2024, leuprolide, triptorelin, and goserelin have been commonly used, with treatment durations ranging from 3 months to lifetime (Table 1).[13,16,17,20,22–37] Most patients reported a 6-month treatment duration. This evidence concerns the gene GNRH1 and neoplasm.